Cargando…

Poor Prognosis Patients with Inoperable Locally Advanced NSCLC and Large Tumors Benefit from Palliative Chemoradiotherapy: A Subset Analysis from a Randomized Clinical Phase III Trial

INTRODUCTION: Poor prognosis patients with bulky stage III locally advanced non–small-cell lung cancer may not be offered concurrent chemoradiotherapy (CRT). Following a phase III trial concerning the effect of palliative CRT in inoperable poor prognosis patients, this analysis was performed to expl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Strøm, Hans H., Bremnes, Roy M., Sundstrøm, Stein H., Helbekkmo, Nina, Aasebø, Ulf
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2014
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4132042/ https://www.ncbi.nlm.nih.gov/pubmed/24807158 http://dx.doi.org/10.1097/JTO.0000000000000184

Ejemplares similares

Concurrent palliative chemoradiation leads to survival and quality of life benefits in poor prognosis stage III non-small-cell lung cancer: a randomised trial by the Norwegian Lung Cancer Study Group
por: Strøm, H H, et al.
Publicado: (2013)

Vinorelbine/carboplatin vs gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity
por: Helbekkmo, N, et al.
Publicado: (2007)

Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer
por: von Plessen, C, et al.
Publicado: (2006)

Vinorelbine and gemcitabine vs vinorelbine and carboplatin as first-line treatment of advanced NSCLC. A phase III randomised controlled trial by the Norwegian Lung Cancer Study Group
por: Fløtten, Ø, et al.
Publicado: (2012)

Differential role of residual metabolic tumor volume in inoperable stage III NSCLC after chemoradiotherapy ± immune checkpoint inhibition
por: Unterrainer, Marcus, et al.
Publicado: (2021)

Is There a Benefit in Receiving Concurrent Chemoradiotherapy for Elderly Patients with Inoperable Thoracic Esophageal Squamous Cell Carcinoma?
por: Zhang, Peng, et al.
Publicado: (2014)

Inoperable poorly differentiated SCC to vertex of scalp progressing into sagittal sinus treated with palliative Cemiplimab
por: Grounds, Katie, et al.
Publicado: (2022)

Association of Planning Target Volume with Patient Outcome in Inoperable Stage III NSCLC Treated with Chemoradiotherapy: A Comprehensive Single-Center Analysis
por: Karin, Monika, et al.
Publicado: (2020)

Longitudinal changes of blood parameters and weight in inoperable stage III NSCLC patients treated with concurrent chemoradiotherapy followed by maintenance treatment with durvalumab
por: Guggenberger, J., et al.
Publicado: (2022)

Severe Radiation-Induced Lymphopenia Attenuates the Benefit of Durvalumab After Concurrent Chemoradiotherapy for NSCLC
por: Jing, Wang, et al.
Publicado: (2022)

Predictive model of the first failure pattern in patients receiving definitive chemoradiotherapy for inoperable locally advanced non-small cell lung cancer (LA-NSCLC)
por: Zhu, Xueru, et al.
Publicado: (2020)

Palliative Treatment for Oral Administration in Cases of Inoperable Malignant Disease
por: Leiper, D. Paterson
Publicado: (1930)

Chemoradiotherapy for Inoperable Carotid Body Leiomyosarcoma: A Case Report and Review of Literature
por: Liu, Cheng-Sheng, et al.
Publicado: (2021)

The clinical utility of dynamic ctDNA monitoring in inoperable localized NSCLC patients
por: Yang, Yin, et al.
Publicado: (2022)

Implementation of durvalumab maintenance treatment after concurrent chemoradiotherapy in inoperable stage III non-small cell lung cancer (NSCLC)—a German radiation oncology survey
por: Käsmann, Lukas, et al.
Publicado: (2020)

Palliative Radiation Therapy for Symptomatic Control of Inoperable Renal Cell Carcinoma
por: Nikolaev, Anatoly, et al.
Publicado: (2015)

Long‐term outcome of concurrent chemoradiotherapy with elective nodal irradiation for inoperable esophageal cancer
por: Jing, Zhao, et al.
Publicado: (2017)

Durvalumab after Chemoradiotherapy for PD-L1 Expressing Inoperable Stage III NSCLC Leads to Significant Improvement of Local-Regional Control and Overall Survival in the Real-World Setting
por: Taugner, Julian, et al.
Publicado: (2021)

Treatment patterns and prognosis of patients with inoperable stage III NSCLC after completion of concurrent chemoradiotherapy ± immune checkpoint inhibition: a decade-long single-center historical analysis
por: Flörsch, Benedikt, et al.
Publicado: (2022)

[F-18] FDG-PET/CT parameters as predictors of outcome in inoperable NSCLC patients
por: Nappi, Antonio, et al.
Publicado: (2015)

Endoscopic palliation of malignant dysphagia: a challenging task in inoperable oesophageal cancer
por: Katsoulis, IE, et al.
Publicado: (2006)

A phase II study of concurrent chemoradiotherapy and erlotinib for inoperable esophageal squamous cell carcinoma
por: Zhao, Chuanhua, et al.
Publicado: (2016)

Multiple Immune Features-Based Signature for Predicting Recurrence and Survival of Inoperable LA-NSCLC Patients
por: Guo, Meiying, et al.
Publicado: (2020)

Understanding the purpose of treatment and expectations in patients with inoperable lung cancer treated with palliative chemotherapy
por: Nowicki, Andrzej, et al.
Publicado: (2015)

Palliative external beam radiotherapy for the treatment of tumor bleeding in inoperable advanced gastric cancer
por: Lee, Yun Hee, et al.
Publicado: (2017)

A Review of Self-Expanding Esophageal Stents for the Palliation Therapy of Inoperable Esophageal Malignancies
por: Kang, Yunqing
Publicado: (2019)

A Retrospective Comparison of Taxane and Fluorouracil-based Chemoradiotherapy in Patients with Inoperable Esophageal Squamous Cell Carcinoma
por: Sun, Xiaojiang, et al.
Publicado: (2016)

Endoscopic debulking resection with additive chemoradiotherapy: Optimal management of advanced inoperable esophageal squamous cell carcinoma
por: Ren, Li-Hua, et al.
Publicado: (2022)

Endostatin and Oxaliplatin‐Based Chemoradiotherapy for Inoperable Esophageal Squamous Cell Carcinoma: Results of a Phase II Study
por: Li, Wenxin, et al.
Publicado: (2019)

Hypofractionated Palliative Radiotherapy in Locally Advanced Inoperable Head and Neck Cancer: CMC Vellore Experience
por: Das, Saikat, et al.
Publicado: (2013)

Stereotactic body radiation therapy for palliative management of pancreatic adenocarcinoma in elderly and medically inoperable patients
por: Ryan, John F., et al.
Publicado: (2018)

Correction to: Palliative external beam radiotherapy for the treatment of tumor bleeding in inoperable advanced gastric cancer
por: Lee, Yun Hee, et al.
Publicado: (2018)

Inoperable Cancer
Publicado: (1901)

A Medical Research Council (MRC) randomised trial of palliative radiotherapy with two fractions or a single fraction in patients with inoperable non-small-cell lung cancer (NSCLC) and poor performance status. Medical Research Council Lung Cancer Working Party.
Publicado: (1992)

IMRT in the treatment of locally advanced or inoperable NSCLC in the pre-durvalumab era: clinical outcomes and pattern of relapses, experience from the Oscar Lambret Center
por: Le Roy, Thomas, et al.
Publicado: (2023)

Pattern-of-failure and salvage treatment analysis after chemoradiotherapy for inoperable stage III non-small cell lung cancer
por: Taugner, Julian, et al.
Publicado: (2020)

Efficacy of Chronomodulated Chemotherapy for Palliation of Hematemesis in Inoperable Gastric Cancer: A Single-Institutional Retrospective Study
por: Biswas, Satadru, et al.
Publicado: (2020)

Clinical evaluation of palliative chemoradiotherapy for metastatic esophageal cancer
por: Ueda, Hiroto, et al.
Publicado: (2017)

Prediction of the preoperative chemoradiotherapy response for rectal cancer by peripheral blood lymphocyte subsets
por: Tada, Noriko, et al.
Publicado: (2015)

Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC
por: Gray, Jhanelle E., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ao85k0elubg0h79ehnadd0ldgf